| SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120093809 | USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS - The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms. | 04-19-2012 |
| 20120041005 | USE OF ALKANOYL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION - Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine. | 02-16-2012 |
| 20110268817 | COMPOUNDS USEFUL FOR THE PREVENTION OR TREATMENT OF ACCOMODATIVE ASTHENOPIA - It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia. | 11-03-2011 |
| 20110262417 | COMPOSITION USEFUL FOR THE PREVENTION OR REDUCTION OF THE PROGRESSION OF PROSTATE CANCER - It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer. | 10-27-2011 |
| 20110217252 | COMPOUND USEFUL FOR TREATING CELLULITE - It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite. | 09-08-2011 |
| 20110189152 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency - A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases. | 08-04-2011 |
| 20110160147 | NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES - The present invention relates to dual-targeting cytotoxic compounds of formula (I) and to their preparation. The described compounds are endowed with tumour specific action, incorporating three functional units: a tumour recognition moiety and a tumour selective enzymatic substrate sequence connected together by means of a spacer. These conjugates are designed to guarantee serum stability and, at the same time, the desired action inside the tumour cells as a result of enzymatic cleavability. [(L-D) | 06-30-2011 |
| 20110136905 | CRYSTALLINE TEGLICAR - The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same. | 06-09-2011 |
| 20110086917 | USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DIESASES - The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally. | 04-14-2011 |
| 20110053902 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS - Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na | 03-03-2011 |
| 20100330200 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT - A combination comprising an atypical retinoid compound, preferably E-4-(3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid and an anticancer drug of the platinum family, preferably cisuplatin, together with a pharmaceutical composition comprising it and a kit for its administration in unitary or in coordinated sequential form. The kit preferably comprises a first formulation of E-4-(3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid dissolved in a mixture of ethanol and cremophor, and susupended in a saline solution, and a second formulation of cisuplatin in saline solution. The combination is used for the preparation of a medicament to inhibit tumor growth and tumor migration, in particular for the treatment of ovarian tumor and/or carcinoma. | 12-30-2010 |
| 20100324003 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS - New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application. | 12-23-2010 |
| 20100305204 | COMPOSITION USEFUL FOR THE PREVENTION OF ADVERSE EFFECT DUE TO THE USE OF PPAR-GAMMA AGONISTS - The present invention relates to the use of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, for the prevention of the adverse effects, such as osteoporosis, weight gain and edema, due to the use of PPAR-gamma agonists selected from the group consisting of spirolaxine or a glitazonederivative selected from the group consisting of roglitazone, pioglitazone androsiglitazone. | 12-02-2010 |
| 20100303896 | 5BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF RESTENOSIS AFTER ANGIOPLASTIC OR ENDOARTHERECTOMY AND DISEASES DUE TO ORGAN FIBROSIS - Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of obstructive vascular lesions following vascular surgery and for the prevention and/or treatment of diseases due to organ fibrosis. | 12-02-2010 |
| 20100298263 | DERIVATIVES OF PARTIALLY DESULPHATED GLYCOSAMINOGLYCANS ENDOWED WITH ANTIANGIOGENIC ACTIVITY AND DEVOID OF ANTICOAGULATING EFFECT - Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds | 11-25-2010 |
| 20100249414 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM - This invention relates to a process for preparing a crystalline form of (4S)-11-(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]qui-noline-3,14(4H,12H)-dione (also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing it from methanol. | 09-30-2010 |
| 20100239497 | OXIDIZED AVIDIN WITH HIGH RESIDENCY TIME IN THE TREATED TISSUES - The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH | 09-23-2010 |
| 20100209442 | DEGLYCOSYLATED AND DESIALIDATED LONG PENTRAXIN PTX3 - Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin. | 08-19-2010 |
| 20100197718 | TREATMENT OF PEDIATRIC TUMORS - A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma. | 08-05-2010 |
| 20100189704 | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose - A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof | 07-29-2010 |
| 20100184972 | SYNTHESIS OF DEOXYBIOTINYL HEXAMETHYLENEDIAMINE-DOTA - A process for the synthesis of deoxybiotinyl hexamethylenediamine0-DOTA is herein described. Said process comprises reacting biotinyl hexamithylenediamine with tri-t-butyl DOTA in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, as the condensing agent, and triethylamine, as a base. | 07-22-2010 |
| 20100166843 | PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE - The present invention relates to pharmaceutical compositions comprising a topoisomerase I inhibitor including, but not limited to, a camptothecin derivative. | 07-01-2010 |
| 20100113504 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS - The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, wherein R is selected from CONHOH, CONHCH | 05-06-2010 |
| 20100093858 | USE OF L-CARNITINE OR OF ALKANOYL L-CARNITINES FOR THE PREPARATION OF A PHYSIOLOGICAL SUPPLEMENT OR MEDICAMENT FOR OPHTHALMIC USE IN THE FORM OF EYE DROPS - Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases. | 04-15-2010 |
| 20100069482 | GEL USEFUL FOR THE DELIVERY OF OPHTHALMIC DRUGS - It is described a gel composed of a mixture of a polymer which forms a gel, a buffer; a saccharide and one or more active ingredients useful for treating diseases of the eyes. | 03-18-2010 |
| 20100068300 | USE OF L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT IN THE FORM OF EYE-DROPS FOR TREATING CORNEAL DISEASES - Use of L-carnitine or a pharmaceutically acceptable salt thereof, for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal oedema. | 03-18-2010 |
| 20100048691 | COMPOSITION USEFUL FOR THE PREVENTION OF TYPE 2 DIABETES AND ITS COMPLICATIONS IN PRE-DIABETIC PATIENTS WITH INSULIN RESISTANCE - The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance. | 02-25-2010 |
| 20100048603 | BROAD-SPECTRUM ANTI-CANCER TREATMENT BASED ON IMINOCAMPTOTHECIN DERIVATIVES - A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma. | 02-25-2010 |
| 20100029759 | COMPOSITION USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES - It is described the use of L-canitine and/or an alkanoyl L-canitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes. | 02-04-2010 |
| 20090312421 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS - It is described a gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles. | 12-17-2009 |
| 20090312286 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS - The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I) | 12-17-2009 |
| 20090275542 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS - Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms. | 11-05-2009 |
| 20090275508 | USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION - It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. | 11-05-2009 |
| 20090257996 | DIETARY SUPPLEMENT ENERGY-PROVIDING TO SKELETAL MUSCLES AND PROTECTING THE CARDIO VASCULAR TRACT - Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines. | 10-15-2009 |
| 20090239893 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN - A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process. | 09-24-2009 |
| 20090221701 | Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure - The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure. | 09-03-2009 |
| 20090186000 | USE OF THYMOSIN ALPHA 1 FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF STAGE IV MALIGNANT MELANOMA - It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases. | 07-23-2009 |
| 20090155260 | USE OF THYMOSIN ALPHA 1 FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin. | 06-18-2009 |
| 20090143464 | Method for preventing and/or treating peripheral Neuropathies induced by the administration of an anticancer agent - A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy. | 06-04-2009 |
| 20090137619 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent - A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy. | 05-28-2009 |
| 20090131515 | Combination of antidiabetic drugs - The combination of R-4-trimethylammonio-3-(tetra-decylcarbamoyl)-aminobutyrate and metformin is disclosed. Said combination of anti-diabetic drugs exerts a synergic action and allows the administration of the two drugs at doses such as to avoid or reduce the occurrence of side effects. The combination is also useful for improving the therapeutic cover far from mealtimes, and in postabsorption and fasting conditions. | 05-21-2009 |
| 20090076146 | USE OF ACETYL L-CARNITINE FOR THE TREATMENT OF FIBROMYALGIC SYNDROME - The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome. | 03-19-2009 |
| 20090062388 | Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain - The invention relates to the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for the preparation of a medication for the preventive therapy for pain. | 03-05-2009 |
| 20090042983 | Use of L-carnitine for the treatment of cardiovascular diseases - The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued at a dose of 4 grams a day by the enteral route | 02-12-2009 |
| 20090012169 | Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia - L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or their pharmaceutically acceptable salts, are used in combination to treat oligoasthenoteratosperia including oligospermia, asthenospermia, and teratospermia. | 01-08-2009 |
| 20080319082 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives - Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours. | 12-25-2008 |
| 20080312265 | Treatment of Drug-Resistant Tumors - A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of drug-resistant tumors and/or for the administration to patients who show polymorphisms in the gene coding for DNA topoisomerase I. | 12-18-2008 |
| 20080300228 | Crystalline Rostafuroxin - New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described. | 12-04-2008 |
| 20080293689 | Compounds with Atypical Antipsychotic Activity - Formula (I) compounds with atypical antipsychotic activity | 11-27-2008 |
| 20080287539 | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause - L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration. | 11-20-2008 |
| 20080279900 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS - A gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles is described. | 11-13-2008 |
| 20080272021 | Package for at Least Two Different Products to be Sold and Used Together - The invention concerns a package ( | 11-06-2008 |
| 20080269307 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus - The invention relates to the use of the acetyl L-carnitine in association with the biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. | 10-30-2008 |
| 20080255232 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation - Compounds useful in the treatment of disorders characterized by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below, where the radicals have the meaning indicated in the description. | 10-16-2008 |
| 20080249152 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents - Formula (I) compounds are described: Formula (I) where the radicals are as defined in the description, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours. | 10-09-2008 |
| 20080234373 | Compound Useful For the Prevention and Treatment of Left Ventricular Hypertrophy in Dialysed Patients - Is described the use of propionyl L-carnitine, or a pharmaceutical salt thereof, for preparing a medicament for the prevention and/or treatment of left ventricular hypertrophy in ESRD or dialysed patients. | 09-25-2008 |
| 20080199844 | Solution for the storage and perfusion or organs awaiting transplantation - A storage solution to maintain and perfuse organs awaiting transplantation comprising (a) an isotonic balanced solution comprising a physiologically acceptable amount of potassium, mono acidic phosphate, biacidic phosphate, chloride, sodium and bicarbonate ions; (b) 50-250 mM glucose; (c) 0.2-20 mM of an alkanoyl L-carnitine or a physiologically acceptable salt thereof; (d) 1-100 mM of L-carnitine or a physiologically acceptable salt thereof; (e) water is described. The storage solution can also include other components such as anti-oxidants and/or chelating agents. | 08-21-2008 |
